Inactief instrument

Andere talen Sorrento Therapeutics, Inc. Deutsche Boerse AG

Aandelen

8STN

US83587F2020

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Ninth Circuit Rules That Biopharmaceutical Company's Announcement Of COVID-19 "Cure" Did Not Violate Securities Laws	10/05
Ninth Circuit Affirms Dismissal Of Putative Securities Class Action Against Biopharmaceutical Company Over Statements It Had Developed A COVID "Cure"	15/04
Sorrento Therapeutics, Inc. Emerged from Bankruptcy	10/04
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend	27/03
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	15/03
Final DIP Financing Approved for Sorrento Therapeutics, Inc.	12/03
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.	11/03
Motion for Asset Sale Approved for Sorrento Therapeutics, Inc.	08/03
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024	02/03
Interim DIP Financing Approved for Sorrento Therapeutics, Inc.	01/03
Health Care Slips on Growth Doubts -- Health Care Roundup	26/02
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.	09/02
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	05/02
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	18/12
Second Modified Joint Liquidation Plan and DIscllosure Statement Approved for Sorrento Therapeutics, Inc.	30/11
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90	07/11
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Chief Financial Officer	07/11
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President	07/11
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	03/11
Motion for Asset Sale Filed by Sorrento Therapeutics, Inc.	30-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sorrento Therapeutics, Inc. Deutsche Boerse AG

Aandelen

8STN

US83587F2020

Andere talen

Filters